Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more.

    Functional solutions for your softgel solubilization formulation challenge

    Solubilization Platform
    Excipients for Drug Formulation Crystallization Inhibitors


    Crystallization Inhibitors

    BASF offers a range of well established crystallization inhibitors that ensure that your drug will not get lost on its way to the point of action in the body.

    Crystallization inhibition is an important factor to maintain drug solubility and bioavailability out of solid and liquid dosage forms in particular. Before it can be adsorbed, recrystallization can happen at any point in time after formulation, during storage or administration, causing bioavailability to plummet and a consequent loss of medication efficacy. BASF offers a range of well established crystallization inhibitors that ensure that your drug will not get lost on its way to the point of action in the body, i.e. our low molecular weight povidones Kollidon® 12 PF and Kollidon® 17 PF or our Kollicoat® MAE 100-55.

    Benefits
    Product range of well established crystallization inhibitors
    Extensive expertise in overcoming solubilization challenges
    Trusted functional performance

    Product Overview

    Focusing on your needs with platform solutions

    This brochure presents an overview of our leading-edge products, grouped in the following platforms: Softgels, Instant and Modified Release, Solubilization and Skin Delivery.